For informational purposes only — not investment advice

← Back to signals

BRKR

LONGINSIDER SELL

BRUKER CORP

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.

Funds
3
Score
3.98
vs SPY
+1.5%
Stock return (since Q-end)
+0.8%
SPY return (since Q-end)
-0.7%
Current price
$60.62
Days to cover (short int.)
5.1d↓-1.7%
as of 2026-09-30 · shares short vs 2026-06-30

News Summary

Neutral

Bruker delivered mixed Q2–Q3 2026 results with organic revenue growth returning (+2.8% in Q2, +0.7% in Q3) and significant non-GAAP EPS expansion (+24.4% in Q3), but GAAP losses persisted and organic growth remains subdued. The company reorganized into four operating segments, targeting $20M additional cost savings in 2027, while selective M&A (Noscendo, Mimetas majority stake) and strategic partnerships (AI, fusion energy) position long-term growth, though U.S. academic funding headwinds remain a near-term constraint.

Red flags

  • •GAAP diluted losses in both Q2 ($(0.41)) and Q3 ($(0.81)) despite non-GAAP profitability
  • •Organic revenue growth slowing to +0.7% in Q3 after modest +2.8% in Q2, well below historical Bruker standards
  • •U.S. academic/government demand remains 'soft' as material headwind, with Q2 revenue down >$15M yoy in this segment
  • •Q2 FY2026 guidance updated for 'currency and tax only,' with +1–2% organic growth guidance unchanged at low end of historical range
  • •One-time 200 bps tariff refund boost to Q2 margins masks underlying operational performance

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Sachem Head CapitalScott Ferguson2.9M+2.9M$175M3.6%—NEW
Viking GlobalAndreas Halvorsen893K+893K$54M0.2%—NEW
Glenview CapitalLarry Robbins252K+252K$15M0.3%—NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where BRKR ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Sachem Head Capital

position #13 of this fund's book

  1. 10GDS Hldgs Ltd$261M
  2. 11Gildan Activewear Inc$188M
  3. 12GOLAR LNG LTD$180M
  4. 13Bruker Corp$175M
  5. 14STMicroelectronics N V$165M
  6. 15Bitdeer Technologies Group$153M
  7. 16Twilio Inc$128M
Glenview Capital

position #36 of this fund's book

  1. 33BAKER HUGHES COMPANY$27M
  2. 34ELEVANCE HEALTH INC FORMERLY$26M
  3. 35MICROCHIP TECHNOLOGY INC.$24M
  4. 36BRUKER CORP$15M
  5. 37NOVARTIS AG$14M
  6. 38DIGITALOCEAN HLDGS INC$13M
  7. 39PRIMO BRANDS CORPORATION$10M

Values are quarter-end position sizes. Shown only for funds where BRKR ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Munch MarkEXEC VP&PRES BRUKER NANO INC.SELL2K$52.87$0.11M2026-09-15↗
Pusch WolfgangPresident BMID GroupSELL3K$56.90$0.20M2026-08-17↗
Munch MarkEXEC VP&PRES BRUKER NANO INC.SELL2K$57.60$0.12M2026-08-14↗
Munch MarkEXEC VP&PRES BRUKER NANO INC.SELL2K$60.25$0.12M2026-07-15↗

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
FMR LLCSC 13G/A23.3M15.0%2026-08-06↗
ORBIS INVESTMENT MANAGEMENT LTDSC 13G/A16.9M11.1%2026-05-15↗
FMR LLCSC 13G/A19.2M12.4%2026-05-06↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.